298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

Episode metadata supplied by the publisher feed · Published Mar 14, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

0:00 35:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 35 minutes long.

When was this The Readout Loud episode published?

This episode was published on March 14, 2024.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!